These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36233288)

  • 1. The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney.
    Gronda E; Vanoli E; Iacoviello M; Caldarola P; Gabrielli D; Tavazzi L
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tubular hypothesis of nephron filtration and diabetic kidney disease.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2020 Jun; 16(6):317-336. PubMed ID: 32152499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
    Thomson SC; Vallon V
    Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System.
    Poursharif S; Hamza S; Braam B
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective Effects of SGLT2 Inhibitors.
    Vallon V
    Heart Fail Clin; 2022 Oct; 18(4):539-549. PubMed ID: 36216484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease.
    Ravindran S; Munusamy S
    J Cell Physiol; 2022 Feb; 237(2):1182-1205. PubMed ID: 34713897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats.
    Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2021 May; 320(5):F761-F771. PubMed ID: 33645318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockout of Na
    Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the benefit of sodium-glucose cotransporter inhibitors over heart failure progression on the kidney side?
    Gronda E; Iacoviello M; Gabrielli D; Caldarola P; Tavazzi L;
    Eur J Intern Med; 2022 Dec; 106():140-143. PubMed ID: 35985952
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes.
    Gronda EG; Vanoli E; Iacoviello M; Urbinati S; Caldarola P; Colivicchi F; Gabrielli D
    Heart Fail Rev; 2023 May; 28(3):723-732. PubMed ID: 35098383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sodium-glucose co-transporter 2 inhibitors: mechanisms of renal action. Implications for diabetes and heart failure].
    Gronda E; Iacoviello M; Caldarola P; Benvenuto M; Cassaniti L; Palazzuoli A; Municinò A; Napoli C; Gabrielli D
    G Ital Cardiol (Rome); 2021 Apr; 22(4):284-291. PubMed ID: 33783448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
    Packer M
    Diabetes Obes Metab; 2020 May; 22(5):734-742. PubMed ID: 31916329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-protein diet: A barrier to the nephroprotective effects of sodium-glucose co-transporter-2 inhibitors?
    Mazzucato M; Fioretto P; Avogaro A
    Diabetes Obes Metab; 2020 Sep; 22(9):1511-1515. PubMed ID: 32350981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibition and kidney protection.
    Nespoux J; Vallon V
    Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
    Takakura S; Takasu T
    Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renal effects of sodium-glucose cotransporter 2 inhibitors in patients with cardiovascular disease with and without chronic kidney disease].
    Benvenuto M; Panzarella G; Shehaj E; Valenti C; Caldarola P; Colivicchi F; Gabrielli D; Iacoviello M;
    G Ital Cardiol (Rome); 2023 Mar; 24(3):188-195. PubMed ID: 36853155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.